我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

两种心肌保护液在婴幼儿心脏手术中心肌保护临床效果的比较

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2015年第3期
页码:
335-339
栏目:
临床研究
出版日期:
2015-01-11

文章信息/Info

Title:
A comparative study of cold and warm cardioplegias in myocardial protection in infants
作者:
辛 梅1; 倪尔连1; 金振晓2; 赵 凯3; 刘 刚1; 欧阳辉1; 张近宝1
(成都军区总医院：1.心血管外科，3.神经外科，四川 成都 610083；
2.第四军医大学西京医院心血管外科，陕西 西安 710032)
Author(s):
XIN Mei1;  NI Er-lian1;  JIN Zhen-xiao2;  ZHAO Kai3;  LIU Gang1;  OUYANG-Hui1;  ZHANG Jin-bao1
(1.Department of Cardiovascular Surgery, 3.Department of Neurosurgery, General Hospital, Chengdu Military Area Command, Chengdu 610083, Sichuan, China；
2.Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
温血; 冷血; 心肌保护; 婴幼儿
Keywords:
warm blooded;  myocardial protection;  infant
分类号:
R541.1
DOI:
-
文献标识码:
A
摘要:
目的:比较两种心肌保护液在婴幼儿术中心肌保护的效果。方法:36例体质量小于15 kg先天性心脏病患儿，随机分为A、B两组：A（n=18）组采用晶体：血液=1∶1冷血停跳液作为心肌保护液，B组（n=18）采用晶体：血液=1:4温血停跳液作为心肌保护液，分别于麻醉诱导前（T1）、升主动脉阻闭后5 min（T2）、开放后5 min（T3）、停机后5 min（T4）、术后1 h（T5）、术后24 h（T6）采集两组患者动脉血行炎性因子肿瘤坏死因子-α（TNF-α）、白介素-8（IL-8）检测；于T1、T5、T6、术后48 h（T7）采集两组患者动脉血行心肌酶谱及心肌损伤标记物检测。记录两组患儿术后呼吸机带机时间、转出ICU时间及手术死亡率、术后并发症发生情况。结果:两组患儿年龄、体质量、预充液组成、心肌保护液用量、体外循环时间、升主动脉阻闭时间、心肌保护液灌注次数等比较，均无显著性差异；B组患儿心肌保护液的血浆胶体渗透压明显高于A组［(14.9±0.8) mmHg vs.(8.0±0.5) mmHg，P<0.01）；B组患儿心肌保护液的灌注压力明显低于A组〔(51±5) mmHg vs.(107±8) mmHg，P<0.01〕；开放升主动脉后心脏自动复跳率略高于A组（94% vs. 89%），B组自动复跳时间明显短于A组〔(0.86±0.15) s vs.(8.63±0.95) s，P<0.01〕；体外循环期间，B组患儿尿量多于A组〔(43±6) ml vs.(29±11) ml，P<0.05〕；两组患儿围术期心肌损伤标记物血浆含量、TNF-α血浆含量无显著差异。炎性因子IL-8血浆含量在T2、T3、T4、T5、T6时，B组浓度明显低于A组，组间比较均有显著性差异（P<0.05，P<0.01）；术后呼吸机辅助时间、ICU滞留时间两组比较无显著性差异。结论:温血心肌保护液可能会在一定程度上改善婴幼儿术中心肌保护效果，但是临床转归未达到显著差异。
Abstract:
AIM:In the present study, we compared the effect of two kinds of cardioplegia on myocardial protection in infants. METHODS: Thirty six patients with congenital heart disease were enrolled in this trial, and all patients had a body weight <15 kg. All patients were randomly divided into two groups: cold blood cardioplegia with 1∶1 ratio of crystal and blood was used as myocardial protective liquid in group A (n=18), whereas warm blood cardioplegia with 1∶4 ratio of crystal and blood was used in group B. Some inflammatory factors like TNF-α and IL-8 were detected before induction of anesthesia (T1), at 5 min after aortic clamping (T2), 5 min after opening (T3), 5 min after operation (T4), 1 h after operation (T5) or 24 h after operation (T6), respectively. Myocardial enzymes and myocardial injury markers were detected at T1, T5, T6 and 48 h after operation (T7). Time of ventilation, ICU stay time, mortality and postoperative complications of both two groups were all recorded. Results: There was no significant difference in the comparison of age, weight, priming solution composition, myocardial protective liquid dosage, cardiopulmonary bypass time, aortic clamping time and myocardial protective liquid filling times between groups. Plasma colloid osmotic pressure of myocardial protection fluid was significantly higher in group B than in group A ［(14.9±0.8) mmHg vs.(8.0±0.5) mmHg, P<0.01］. Group B had lower cardioplegia perfusion pressure compared with group A ［(51±5) mmHg vs.(107±8) mmHg, P<0.01］. After opening ascending aorta, group B had higher automatic rebeating rate (94% vs. 89%) and shorter rebeating time than group A ［(19.43±2.26) s vs.(64.86±2.72) s, P<0.01］. During cardiopulmonary bypass, patients in group B excreted more urine ［(43±6) ml vs.(29±11) ml, P<0.05］. There was no significant difference in regard to myocardial injury markers and TNF-α between groups during the perioperative period. At T3 time, concentration of inflammatory factor IL-8 plasma was significantly lower in group B than in group A (P<0.05, P<0.01). There was no significant difference in regard to postoperative mechanical ventilation time and ICU stay time between groups. Conclusion: The warm blood myocardial protection fluid may improve the effects of myocardial protection to a certain extent, but there is no significant difference in clinical outcome.

参考文献/References

[1]武书玲.未成熟心肌保护的研究进展[J].医学综述,2013,19(14):2517-2520.
[2]Hammon JW Jr.Myocardial protection in the immature heart[J].Ann Thorac Surg,1995,60(3):839-842.
[3]Yamamoto F.Metabolic characterristics of immature myocardium[J].Gen Thorac Cardiovasc Surg,2010,58(4):171-173.
[4]Magovern GJ Jr,Flaherty JT,Gott VL,et al.Failure of blood cardioplegia to protect myocardium at lower temperatures[J].Circulation,1982,66(2pt 2):I60-I67.
[5]Williams WG,Rebeyka IM,Tibshirani RJ,et al.Warm induction blood cardioplegia in the infant- a technique to avoid rapid cooling myocardial contracture[J].J Thorac Cardiovasc Surg,1990,100(6):896-901.
[6]Rosenkranz E,vinteu-johansen J,Buckerg GD,et al.Benefits of normorbermic induction of cardiopiegia in energy-depleted hearts,with maintenance of arrest by multi-dose cold blood cardioplegia infusions[J].J Thorac Cardiovasc Surg,1982,84(5):667-677.
[7]Mohara J,Tsutsumi H,Takeyoshi I,et al.The optimal pressure forinitial flush with UW solution in heart procurement[J].J Heart Lung Transplant,2002,21(3):383-390.
[8]刘东璐,吴伯娟,陶仁海. 未成熟心肌保护与停搏液灌注压的试验研究［J］. 河北医药, 2008, 30(8):1124-1125.
[9] 冯锐,许林海.温血灌注心肌保护的研究进展[J].心脑血管病防治,2009,9(2):143-144,102.
[10]董培青.体外循环损伤与保护[M].北京:人民卫生出版社,2007:198-199.
[11]Imura H,Modi P,Pawade A,et al.Cardiac troponin I in neo-nates undergoing the arterial Switch operation[J].Ann Thorac Surg,2002,74(6):1998-2002.
[12]Fiore AC,Swartz MT,Nevett R,et al.Intermittent antegradetepidrsus cold blood cardioplegia in elective myocardial re-va-scularization[J].Ann Thorac Surg,1998,65(6):1559-1564.
[13]Elwatidy AM,Fadalah MA,Bukhari EA,et al.Antegradecrystalloid cardioplegiavsantegrade/retrograde cold and tepid blood cardioplegia in CABG[J].Ann Thorac Surg,1999,68(2):447-453.
[14]Hayashida N,Ikonomidis JS,Weisel RD,et al.The optimal cardioplegic temperature[J].Ann Thorac Surg,1994,58(4):961-971.
[15]Hayashida N,Isomura T,Sato T,et al.Minimally diluted tepid blood cardioplegia[J].Ann Thorac Surg,1998,65(3):615-621.

备注/Memo

备注/Memo:
收稿日期: 2014-07-30.
通讯作者：张近宝，主任医师，主要从事复杂先心病及重症瓣膜疾病治疗和研究Email：cpbchengzongxin@sina.cn
共同通讯作者：金振晓，副主任医师，主要从事心脏手术脏器保护研究Email：jinzx10262@yahoo.com.cn
作者简介：辛梅，副主任技师，硕士Email：cpbchengzongxin@sina.cn
更新日期/Last Update: 2015-02-03